|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
AU2018378812B2
(en)
*
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
KR20210086601A
(ko)
*
|
2018-08-02 |
2021-07-08 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL280536B2
(en)
*
|
2018-08-02 |
2024-12-01 |
Dyne Therapeutics Inc |
Complexes targeting transferrin receptor and uses thereof
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
AU2021206234A1
(en)
*
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
SI4126066T1
(sl)
|
2020-03-27 |
2026-04-30 |
Avidity Biosciences, Inc. |
Sestavki in postopki zdravljenja mišične distrofije
|
|
WO2021226107A1
(en)
*
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
JP2023524812A
(ja)
*
|
2020-05-08 |
2023-06-13 |
エムペグ エルエイ リミテッド ライアビリティ カンパニー |
リンカー化合物
|
|
JP2023535078A
(ja)
*
|
2020-07-23 |
2023-08-15 |
ダイン セラピューティクス，インコーポレーテッド |
筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
|
|
CN116194470B
(zh)
*
|
2020-07-23 |
2025-10-03 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
IL303332A
(en)
*
|
2020-12-04 |
2023-07-01 |
Dyne Therapeutics Inc |
Antibody-oligonucleotide complexes and their uses
|
|
CA3202832A1
(en)
*
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2022197554A1
(en)
*
|
2021-03-16 |
2022-09-22 |
University Of Massachusetts |
Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins
|
|
JP2024525608A
(ja)
*
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
AU2022309238A1
(en)
*
|
2021-07-09 |
2024-01-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
JP2024525611A
(ja)
*
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2023023031A2
(en)
*
|
2021-08-17 |
2023-02-23 |
Blaze Bioscience, Inc. |
Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
|
|
WO2023034409A1
(en)
|
2021-09-01 |
2023-03-09 |
Biogen Ma Inc. |
Anti-transferrin receptor antibodies and uses thereof
|
|
KR20240067118A
(ko)
*
|
2021-09-29 |
2024-05-16 |
아이오니스 파마수티컬즈, 인코포레이티드 |
접합된 올리고뉴클레오타이드 및 이의 용도
|
|
JP2025500481A
(ja)
|
2021-12-22 |
2025-01-09 |
サプリーム テクノロジーズ，ベー．フェー． |
筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
|
|
US20250057971A1
(en)
|
2021-12-22 |
2025-02-20 |
Sapreme Technologies B.V. |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
WO2023121444A1
(en)
|
2021-12-22 |
2023-06-29 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
TW202345894A
(zh)
*
|
2022-01-07 |
2023-12-01 |
美商密瑞克公司 |
靶向表現於肌肉細胞表面的蛋白質之組織特異性顯像及治療劑
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4612184A1
(en)
*
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4480964A1
(en)
*
|
2023-06-22 |
2024-12-25 |
Vect-Horus |
Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
|
|
CN121794291A
(zh)
*
|
2023-06-22 |
2026-04-03 |
维克塔-霍洛斯公司 |
转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途
|
|
WO2025160275A1
(en)
|
2024-01-24 |
2025-07-31 |
Arrowhead Pharmaceuticals, Inc. |
Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
|